Latest News

Tiziana Life Sciences to Host Investor Call

04 November 2022

NEW YORK, November 04, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

03 November 2022

New York, November 3, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...

Read more

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

02 November 2022

NEW YORK, November 02, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced completion of enrollment of the first patient cohort (n=4)...

Read more

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

26 October 2022

NEW YORK, October 26, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the start of enrollment of the first patient cohort...

Read more

Article: BioSpace published an article on Tiziana's plan to submit an IND for Intranasal Alzheimer's Treatment

19 October 2022

Tiziana Plans IND for Intranasal Alzheimer's Treatment with Promising CNS History

Read more

Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference

19 October 2022

New York- October 19, 2022 - Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022...

Read more

Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

12 October 2022

  • Company continues to advance foralumab in CNS-related inflammatory diseases

NEW YORK, Oct. 12, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

29 September 2022

New York, September 29, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief...

Read more

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

28 September 2022

  • Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit
  • Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit
  • Effect of nasal anti-CD3 (foralumab) in patient with Progressive MS” poster exhibit
  • Howard L. Weiner, M.D. of Brigham...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

23 September 2022

New York, September 23, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical...

Read more

Page 2 of 25 Previous Next